AZD0156: A Selective ATM Kinase Inhibitor for Cancer Rese...

2026-04-07

AZD0156: Empowering Cancer Research with a Selective ATM Kinase Inhibitor

Principles and Setup: Targeting the ATM Signaling Pathway in Cancer

Understanding and manipulating the DNA damage response (DDR) is central to modern cancer biology and therapy development. At the heart of this network is Ataxia Telangiectasia Mutated (ATM) kinase, a serine/threonine kinase of the PIKK family, which orchestrates the cellular response to DNA double-strand breaks (DSBs). ATM activation triggers downstream signaling for DNA repair, checkpoint control, and genomic stability regulation—key factors in both tumor suppression and cancer cell survival. AZD0156 is a next-generation, orally bioavailable, and highly selective ATM kinase inhibitor for cancer research, offering sub-nanomolar potency (≥1000-fold selectivity over other PIKKs) and robust performance in both in vitro and in vivo models (AZD0156 product page).

This compound has become a pivotal tool in dissecting the ATM signaling pathway, enabling researchers to probe the interdependencies of DNA repair, cell fate, and metabolic adaptation. The selectivity of AZD0156 ensures minimal off-target effects, making it especially valuable in preclinical cancer models and translational workflows exploring checkpoint control modulation and DNA double-strand break repair inhibition.

Step-by-Step Experimental Workflow with AZD0156

1. Compound Handling and Storage

Preparation: AZD0156 is supplied as a high-purity solid (≥98%, HPLC/NMR validated) by APExBIO. Dissolve in DMSO to ≥23.1 mg/mL with gentle warming, or in ethanol to ≥5.49 mg/mL. Note: The compound is insoluble in water.
Storage: Store the solid at -20°C. For working solutions, prepare fresh aliquots and avoid long-term storage to preserve potency and selectivity (AZD0156 storage conditions).

2. Experimental Design: ATM Inhibition in DNA Damage Response Research

Cell Line Selection: Optimal models include HR-proficient and HR-deficient cancer cells, such as high-grade serous ovarian cancer (HGSOC) lines, to explore differential responses to ATM blockade.
Dosing Strategy: Standard in vitro concentrations range from 10 nM to 1 μM, leveraging the sub-nanomolar potency of AZD0156 for precise ATM inhibition.
Combination Studies: Synergistic effects are observed when AZD0156 is combined with DNA double-strand break agents (e.g., ionizing radiation, PARP inhibitors) or metabolic modulators like fenofibrate. For example, the Heliyon study demonstrated that ATM inhibition with AZD0156 synergizes with fenofibrate, inducing senescence in HGSOC cells via checkpoint control and metabolic disruption.
Readouts: Assess DDR pathway inhibition using γH2AX and pCHK2 immunoblotting, cell cycle analysis, viability assays, and senescence markers. For DNA repair pathway interrogation, employ homologous recombination (HR) and non-homologous end joining (NHEJ) reporter assays.

3. Protocol Enhancements and Optimization

Timecourse Optimization: AZD0156 demonstrates rapid ATM inhibition (<1 hour), with sustained effects for 24–48 hours. For acute checkpoint control modulation, pre-treat cells 1–2 hours before DNA damaging agent exposure.
In Vivo Application: Oral administration in preclinical cancer models utilizes dosing regimens (e.g., 2–10 mg/kg) that recapitulate clinically relevant ATM pathway inhibition and potentiate antitumor responses to DSB-inducing agents.

Advanced Applications and Comparative Advantages

AZD0156 is uniquely positioned at the interface of DDR and metabolic research, unlocking new experimental avenues in cancer therapeutic development:

Combination Therapeutics: As illustrated by Chen et al. (2020), ATM kinase inhibition synergizes with fenofibrate, a PPARα agonist, in HGSOC models. This synergy induces cellular senescence, offering a promising strategy for HR-proficient tumors resistant to PARP inhibitors. These findings extend the utility of AZD0156 beyond traditional DNA damaging agent combinations, highlighting its role in metabolic targeting.
Precision Oncology: AZD0156's >1000-fold selectivity ensures that observed phenotypes are specifically attributable to ATM inhibition, unlike less selective PIKK family kinase inhibitors. This precision is critical for both mechanistic studies and translational research, as reviewed in "AZD0156 and the Future of ATM Inhibition", which outlines the clinical strategies and mechanistic rationale for deploying AZD0156 in advanced cancer therapeutic research.
Overcoming Resistance: In solid tumor research, particularly for HR-proficient and chemoresistant cancers, AZD0156 enables the exploration of alternative treatment paradigms. This contrasts with findings in "AZD0156: Unlocking ATM Kinase Inhibition for Precision Ca...", where the focus is on DNA repair and checkpoint control rather than metabolic vulnerabilities, thus complementing the metabolic-synergy insights from the Heliyon study.

For researchers requiring a deeper dive into workflow optimization and mechanistic targeting, the in-depth guide "AZD0156: Selective ATM Kinase Inhibitor for Cancer Research" offers practical insights into experimental design and quality control, underscoring the compound’s sub-nanomolar ATM inhibition and APExBIO’s rigorous supply standards.

Troubleshooting and Optimization Tips

Compound Solubility: Always dissolve AZD0156 in DMSO or ethanol as per the recommended concentrations. Avoid aqueous buffers to prevent precipitation. For cell-based assays, dilute the DMSO stock into culture media immediately before use, maintaining a final DMSO concentration ≤0.1% to minimize cytotoxicity.
Batch Consistency: Source AZD0156 from APExBIO to ensure consistent purity and performance. Variability in ATM inhibition or off-target effects can often be traced to compound quality.
Assay Timing: For checkpoint control research, monitor ATM pathway inhibition markers (e.g., decreased pCHK2) within 1 hour of treatment. For longer-term phenotypes (e.g., senescence, cell death), extend observation to 48–72 hours to capture delayed effects.
Combination Index Calculation: When assessing synergy (e.g., with fenofibrate or PARP inhibitors), calculate the combination index (CI) using the Chou-Talalay method for quantitative synergy assessment. In the Heliyon study, the combination of ATM inhibitor and fenofibrate revealed CI values <1, confirming synergistic action.
Rescue Controls: Include ATM wildtype and ATM-deficient controls or use RNAi/CRISPR validation to confirm on-target effects of AZD0156 in your experimental system.

Future Outlook: Translating ATM Inhibition into Clinical Impact

AZD0156 is currently being evaluated in early phase clinical trials for advanced cancers, reflecting its translational promise as an oral ATM kinase inhibitor for cancer therapy. The ongoing integration of DNA damage response pathway inhibitors with metabolic modulators marks a paradigm shift in cancer therapeutic research—one in which AZD0156 is a central tool. As summarized in "AZD0156: Precision ATM Kinase Inhibition to Unravel DNA R...", the compound’s unique ability to modulate both DNA repair and metabolic adaptation is catalyzing new precision oncology strategies.

Looking forward, the strategic use of AZD0156 in solid tumor research, especially in HR-proficient or chemoresistant models, will continue to refine our understanding of ATM’s role in genomic stability research and checkpoint control. With its robust selectivity, oral bioavailability, and compatibility with diverse combination regimens, AZD0156 stands out as a highly selective kinase inhibitor for next-generation cancer biology and therapeutic innovation.

References

APExBIO is proud to supply AZD0156 to the global research community, supporting breakthrough cancer biology and translational studies in DNA double-strand break repair, checkpoint control, and beyond.